You are here

New Agents for the Treatment on Mycobacteria Avium Infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI165272-01A1
Agency Tracking Number: R41AI165272
Amount: $600,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA21-262
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-04-01
Award End Date (Contract End Date): 2024-03-31
Small Business Information
400 Farmington Avenue
Farmington, CT 06032-3449
United States
DUNS: 080447260
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (860) 486-9451
Business Contact
Phone: (603) 646-6481
Research Institution
Sponsored Program Services 438 Whitney Road Extension, Unit 1006
STORRS, CT 06269-1006
United States

 Nonprofit College or University

Abstract: Non-Tuberculosis Mycobacteria (NTM) are responsible for widespread, life threatening infections
of the lungs, skin, lymphatic and hematological systems. The rapid, global spread of resistant organisms has
significantly reduced the number of agents that can be used effectively to treat these infections. Of specific
clinical relevance are the slow-growing Mycobacterium avium complex (MAC) comprised of M. avium, M.
intracellulare and M. chimaera. MACs are widely distributed throughout the environment, often found in soil,
water and airborne particulates. Mycobacterial infections are a growing cause of concern in
immunocompromised individuals with underlying comorbidities and represent a significant threat as opportunistic
pathogens. Over the past three decades, the incidence of infections caused by MAC NTMs have increased more
than 30-fold. Change in the world climate is allowing these once-unknown environmental mycobacteria to flourish
and establish themselves as an increasingly common source of deadly infections, accounting for approximately
40% of the pulmonary infections (NTM lung disease) found in immunocompromised patients. Currently in the
United States, the prevalence of MAC NTM infections is approximately 50 per 100,000 population, equating to
more than 200,000 new cases annually. It is estimated that this number will grow at a rate of +8% per year. The
costs associated with treatment of NTM-related infections exceeded $800M in 2018.
MAC NTM-LD represents an unmet clinical need as there are few safe and effective drugs available to combat
the infections they cause. Furthermore, because standard antibiotics have so much environmental exposure,
many MAC isolates are natively drug resistant. QMD is focused on the development of an inhaled therapeutic
that inhibits the essential NTM enzyme dihydrofolate reductase (DHFR), which is involved in the biosynthesis of
the nucleic acid building blocks that are a key player in the folate cycle and a validated antibiotic drug target.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government